Ranbaxy Claims ‘Buyer’s Remorse’ Is Behind FDA Rescission Of ANDA Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Suit argues FDA granted tentative approvals of generic versions of Valcyte and Nexium to maintain Ranbaxy’s marketing exclusivity.